Pharma valuations: treading water
This article was originally published in Scrip
Executive Summary
Investing in pharmaceutical companies was once considered a defensive strategy for fund managers looking for consistent and steady growth while buying biotech has always been seen as a riskier strategy that could potentially yield more exciting returns. It is now clear that those days are well gone.